NCT02633020 - Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 13, 2016

Primary Completion Date

April 11, 2017

Study Completion Date

May 2, 2017

Conditions

Type II Refractory Celiac Disease (RCD-II)In-situ Small Bowel T-cell Lymphoma

Interventions

BIOLOGICAL

AMG 714

Administered via a 120-minute IV infusion for a total of 7 times over 10 weeks.

BIOLOGICAL

Placebo

Administered via a 120-minute IV infusion for a total of 7 times over 10 weeks.

Trial Locations (6)

Clinical Site, San Diego

Clinical Site, New York

Clinical Site, Tampere

Clinical Site, Paris

Clinical Site, Amsterdam

Clinical Site, Madrid